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A central challenge in systems biology and medical genetics is to understand how
interactions among genetic loci contribute to complex phenotypic traits and human
diseases. While most studies have so far relied on statistical modeling and
association testing procedures, machine learning and predictive modeling
approaches are increasingly being applied to mining genotype-phenotype
relationships, also among those associations that do not necessarily meet statistical
significance at the level of individual variants, yet still contributing to the combined
predictive power at the level of variant panels. Network-based analysis of genetic
variants and their interaction partners is another emerging trend by which to explore
how sub-network level features contribute to complex disease processes and related
phenotypes. In this review, we describe the basic concepts and algorithms behind
machine learning-based genetic feature selection approaches, their potential benefits
and limitations in genome-wide setting, and how physical or genetic interaction
networks could be used as a priori information for providing improved predictive
power and mechanistic insights into the disease networks. These developments are
geared toward explaining a part of the missing heritability, and when combined
with individual genomic profiling, such systems medicine approaches may also
provide a principled means for tailoring personalized treatment strategies in the
future.Introduction
Most disease phenotypes are genetically complex, with contributions from combinations
of genetic variation in different loci. A major challenge of medical genetics is to deter-
mine a set of genetic markers, which when combined together with conventional risk
factors could be used in predicting an individual's susceptibility to developing various
complex disorders. The recent advances and wide availability of genetic technologies,
such as those based on genome-wide association (GWA) and next-generation sequencing
(NGS), have allowed for the in-depth analysis of the variation contained in the human
genome. In particular, these technologies are enabling the investigation of the genetic
architecture of complex diseases, with the aim of constructing more accurate disease risk
prediction models that would eventually facilitate effective approaches to personalized
prevention and treatment alternatives for many diseases [1,2]. While GWA studies have
successfully identified hundreds of genetic variants that are associated with complex© 2013 Okser et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
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tical association testing approaches only capture a small portion of the heritability and
even an aggregate of these effects is often not predictive enough for clinical utility, leaving
open the question of what may explain the remaining or ‘missing heritability’ [7].
Suggested explanations include, for instance, contributions from rare and structural
variants, genotype–environment and gene-gene interactions and sample stratification, or
simply that complex traits truly are affected by thousands of variants of small effect size
[8,9]. The relative contributions of these and other factors remain poorly understood,
which is hindering the development of improved models for disease risk assessment.
Given the multi-factorial nature of complex diseases, many authors have reiterated
the concept of interactions among genetic loci, so-called epistatic interactions, as one
of the major factors contributing to the missing heritability [9,10]. Epistatic genetic
interactions between or within genes are thought to be profoundly important in the de-
velopment of many complex diseases, but these interactions are often beyond the reach
of the conventional single-variant association testing procedures [11-14]. There exist
also increasingly complex interactions between genetic variants and environmental
factors that may contribute to the disease risk on an individualized basis. Consequently,
it has been argued that we should move away from the traditional ’one variant at a
time’ approach toward a more holistic, network-centric approaches, which take into ac-
count the complexity of the genotype-phenotype relationships characterized by mul-
tiple gene-gene and gene-environment interactions [15,16]. Although the conventional
statistical significance testing procedures have successfully identified several susceptibil-
ity loci, it has become clear that many of the true disease associations may be much
lower down on the ranked list of hits, compared to the top hits with the most statistical
support [4,17,18]. Ignoring the potential risk variants in this ‘gray zone’ of genetic infor-
mation is likely to result in models that are missing an important proportion of the
quantitative variation in heritability. Therefore, it may be that most of the heritability is
hidden rather than missing, but has not previously been detected because the individual
effects are too small to pass the stringent significance filters used in many studies, yet
still having significant contribution to the predictive power at the level of variant or
subject subsets, or when combined with non-genetic risk factors.
Here, we discuss how computational machine learning approaches can utilize hidden
interactions among panels of the genetic and other risk factors, predictive of the indi-
vidual disease risk by means of implementing genetic feature selection procedures and
network-guided predictive models. In contrast to the conventional population-level as-
sociation testing, which often detect only a few variants with statistical support beyond
the genome-wide significance level (e.g. p < 10-8), machine learning algorithms place
special emphasis on maximizing the predictive accuracy at the level of individual
subjects. The goal of feature selection is to identify such a panel of genetic and other
risk factors, which result in a model that optimally predicts the phenotypic response
variables, either the class labels in case-control classification (e.g. disease vs. healthy),
or quantitative phenotypes in regression problems (e.g. height prediction). While epi-
static genetic interactions may easily end up being averaged out in statistical association
models, machine learning-based predictive modeling can also take into account those
individual effects that are dependent on interactions with other variants or environ-
mental exposures, making these models convenient for developing predictive strategies
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selection strategies for constructing prediction models may lead to sub-optimal predic-
tion accuracies [17]. In another example, hundreds of genetic markers, many of which
did not originally meet the genome-wide level of statistical significance, were combined
into a predictive model of type 1 diabetes risk [18]. Even though diabetes is known to
involve many biological pathways, the large number of variants required may partly be
attributed also to the selection of variants based solely on their individual p-values,
which does not take into account any gene-gene interactions.
While machine learning-based computational approaches may provide a convenient
framework for making use of the whole spectrum of genetic information when
predicting an individual’s risk of developing a disease, these developments are still in
their very early stages. Implementation of highly scalable computational algorithms for
genetic feature selection is a key for making these frameworks effective enough for
mining data from current GWA studies, in which more than a million genetic variants
are assayed in thousands of individuals, not to mention the emerging data from NGS
studies, such as the 1000 Genomes project [19]. Recent improvements in constructing
accurate and scalable machine learning-based predictive models will be discussed in
Section 2. Another pressing problem inherent in every machine learning application is
the challenge of how to evaluate the predictive capability of the constructed models, in
order to avoid stating over-optimistic prediction results [20]. Model validation
approaches are described in Section 3. One approach to reducing the massive search
spaces and computational complexities is to use additional biological information in
the model construction process. There are already several successful examples of how
to make use of physical protein interaction networks when mining data from GWA
studies in the search of, for instance, regulatory models [16], epistatic interactions [21],
or disease genes [22]. In Section 4, we take the next step of network level analysis of
genetic variants and review recent data mining solutions capable of systematically util-
izing functional information from the interaction networks as a priori information
when building disease prediction models. Finally, in Section 5, we will list some current
challenges and possibilities as future directions toward improved understanding of indi-
vidual predisposition to genetically complex diseases such as cancers.Selection of genetic risk factors for machine learning-based prediction
models
Rather surprisingly, the use of machine learning method in the context of genome-wide
data on genetic variants has yielded a relatively limited number of studies until the very
recent years (for a systematic literature review, see [20]), compared to the large number
of machine learning studies on other types of genomic datasets, especially genome-
wide gene expression profiles. Further, the combination of predictive modeling and
advanced feature selection algorithms have been implemented in an even more
restricted set of studies, even though these have generally yielded quite positive results
[15,23]. Indeed, many studies have demonstrated that the use of feature selection
approaches are capable of improving the prediction results beyond that when the same
model is implemented on features selected solely through prior knowledge of the dis-
ease or on those genetic variants which reach genome-wide statistical significance
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high-dimensional datasets originating from GWA or NGS studies, due to a number of
experimental and computational issues, many of which are different from those faced
when using data from microarray gene expression profiling. Further, in order to
construct accurate and reliable predictive models of complex phenotypes based on
genome-wide profiles of genetic variants, it is essential to have an understanding of
how to identify predictive features both individually and in groups of variant subsets,
and how different feature selection approaches can deal with issues such as epistatic
interactions and high-dimensional datasets [15]. Feature selection methods in machine
learning can broadly be divided into filter, wrapper and embedded methods. This
categorization is not strict, and each of the approaches has its own advantages and
disadvantages which are, in turn, very problem dependent. Next, we briefly describe
each feature selection category and consider some representative examples of each.Filter methods
Filter methods for genetic feature selection are the most common in GWA studies due
to the simplicity of their implementation, low computational complexity, and the
human interpretability of the results. In their simplest form, filter methods calculate a
univariate test statistic separately for each genetic feature, and the features are then
ranked based on the observed statistic values. The highest ranked features form the
final set of selected features, on which a predictive model may be subsequently trained.
The number of features to be selected is either decided in advance or determined by a
pre-defined significance threshold for the test statistic. Several well-known statistical
tests have been used in GWA studies, including the Fisher’s exact test and Armitage
trend test [26-28], and an increasing number of statistical approaches are being
developed for rare variants and the NGS data [29-31]. Since this feature selection ap-
proach requires only a single pass through the whole data, single-locus filters can be
straightforwardly applied to even the largest genome sequencing datasets. Along with
the multiple testing problem, the primary drawback of the single-locus filter methods is
that they do not take account of the interactions between the features, which may lead
to selection of both false positives, such as redundant loci, and false negatives due to
epistasis interactions between or within loci [12,13,15]. More advanced filter methods
can also select specific risk variant combinations that are associated with a disease risk.
For instance, multifactor dimensionality reduction (MDR) is a non-parametric method
that can detect statistically significant genetic interactions among two or more loci in
the absence of any marginal effects, even in relatively small sample sizes [32]. While
proved to be useful for association testing, however, it has been argued that the
statistics being used to identify variants or their combinations, typically p-values for
disease risk association, are perhaps not the most appropriate means for evaluating the
predictive or clinical value of the genetic profiles [33].Wrapper methods
Wrapper methods consist of three components: a search algorithm for systematically
traversing through the space of all possible feature subsets, a scoring function for evalu-
ating the predictive accuracy of the feature subsets, and the learning algorithm around
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of the features grows exponentially with the number of genetic variants screened (say
n), testing all the feature subsets (2n) is computationally infeasible (n is on the order of
a million in a typical GWA study and much larger in NGS studies). Therefore, one
must resort in practice to local search methods that do not guarantee finding the opti-
mal subset but, nevertheless, usually lead to good local optima. For example, the greedy
forward selection adds one feature at a time to the set of selected features after
checking which of the remaining features would improve the value of the scoring func-
tion the most. Thus, the whole data set is traversed through once for each selected fea-
ture. To avoid getting trapped in poor local optima during the search in the complex
and high-dimensional genetic landscapes, modified local search strategies can be
utilized, including the backtracking option or several variations of evolutionary
algorithms. The most popular scoring functions used with wrapper methods are the
prediction error on the training set, a separate validation set, or cross-validation error.
The feature selection can be in principle wrapped around any learning method, but it is
beneficial if the method can be efficiently trained or if the already learned model can be
efficiently updated. Indeed, for some learning methods, such as regularized least-squares
(RLS), the search process can be considerably accelerated with computational short-cuts
for scoring function evaluation [23]. These inbuilt short-cuts bring the methods closer to
the next category of the selection methods, namely the embedded ones.Embedded methods
Embedded methods have the feature selection mechanism built into the training algo-
rithm itself [35], that is, the predictive models they produce tend to depend only on a
subset of the original features. Perhaps the most well-known embedded method is
LASSO (least absolute shrinkage and selection operator), which is also recently being
applied to a larger number of GWA studies [20,25,36-38]. While only a few machine
learning approaches, in fact, allow for scaling-up to the genome-wide level, this has
been made possible in LASSO by the recently developed model training algorithms,
such as those based on the coordinate descent methods, which are computationally
very efficient. The problem setup resembles the wrapper approach in the sense that
there is an objective function for which one performs a stochastic search, such as cyclic
or stochastic coordinate descent, in order to find a global optimum. Basically, the
search algorithm goes through each feature at a time, and updates the corresponding
coefficient in the linear model under construction. The objective function consists of a
scoring metric such as the mean squared error (MSE) on the training data and a
regularization term that favors sparse linear models, that is, it tends to push the search
algorithm towards such models that have only a few nonzero parameters. Typically, co-
ordinate descent passes through the whole data set only a couple of times before con-
vergence, but the number of passes depends on the properties of the data, the desired
sparsity level, and the other possible hyperparameters. Wrappers and embedded
methods are known to have the ability to produce better results than filter methods in
many applications [23,25,39], but if not implemented correctly, they can easily lead to
the models failing to generalize beyond the training data, underscoring the importance
of rigid evaluation of the prediction models.
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phenotypes
One of the main challenges in feature selection is the accurate estimation of the predic-
tion performance of the machine learning models on new samples unseen at the
training phase, especially in settings in which the data is high-dimensional and the
number of labeled training data is relatively small. Given the massive dimensionality of
modern GWAS and NGS studies, it is in fact not very hard to find genetic features that
can almost perfectly fit to a small training set but fail to generalize to unseen data, a
phenomenon known as model overfitting. Therefore, the models learned from genetic
data should always be tested on independent data not used for training the model. In
case the number of labeled data is small, one must resort to cross-validation
techniques that repeatedly split the data into training and test sets, and the predictive
accuracy is reported as an average over the test folds. In many applications of genomic
predictors, there are a number of examples of the so-called selection bias [40], mean-
ing that the cross-validation is used to estimate the performance of the learning algo-
rithm only, but not the preliminary feature selection done on the whole data, therefore
leading to information leak and grossly over-optimistic results. Further, if cross-
validation is used for selecting the hyper-parameters of the learning algorithm or for
feature selection, this needs to be done within an internal cross-validation loop, separ-
ately during each round of an outer cross-validation loop [40-43]. This two-level tech-
nique is sometimes referred to as the nested cross-validation [42,44]. An example
demonstrating the behavior of a cross-validation error when it is used as a selection cri-
terion with greedy forward selection is presented in Figure 1. The error curve that con-
stantly decreases as a function of the number of selected features clearly indicates that
the cross-validation becomes a part of the training algorithm itself in the inner loop,
and therefore it cannot be trusted as a measure of true prediction performance for
unseen data.
The evaluation of the predictive power is important also when considering predictive
models constructed on the basis on statistical significant variants. For instance, there
are numerous observations showing that the increases in the proportion of variance
explained by significant variants does not go hand in hand with improved genetic pre-
diction of disease risk. For instance, when using statistical modeling on the single
training sample only, a panel of thousands of non-significant variants collectively could
capture over one-third of the heritability for schizophrenia, but the same panel only
explained a few percent of disease susceptibility in another replication cohort [8]. Simi-
larly, while the statistical explanation power of the genetic variation in human height
could be substantially increased by considering increasing number of common variants
in a single population sample [45], the proportion of variance accounted for in other
independent samples was much smaller [46]. These examples underscore the import-
ance of rigid validation of the predictive accuracy of the models based on genetic
profiles. While external cross-validation is a valid option, it is not free of any study-
specific factors. For example, if there is a problem during the genotyping phase, it will
appear also in any training and test data splits. These errors, stemming from problems
during the experimental design and/or quality control have led for the need to re-
evaluate the established methods and use caution when claiming replication [47]. The
recommended option for truly validating the generalizability of predictive risk models
Figure 1 The figure illustrates how the external and internal cross-validation results behave as
functions of the number of selected features. The external-cross validation consists of three training/test
splits. The wrapper-based feature selection method, greedy RLS [23], is separately run during each round of
the external cross-validation. Greedy RLS, in turn, employs an internal leave-one-out cross-validation on the
training set for scoring the feature set candidates. The red curve depicts the mean values over these
internal cross-validation errors. As can be easily observed from the blue curve, this internal cross-validation
MSE used for the model training keeps constantly improving, which is expected, because the internal cross-
validation quickly overfits to the training data when it is used as a selection measure. The blue curve
depicts the area under curve (AUC) on the test data, held out during the external cross-validation round,
that is, data completely unseen during the internal cross-validation and feature selection process. In
contrast to the red curve, the blue curve starts to level off soon after the number of selected variants
reaches around 10, indicating that adding extra features is not beneficial anymore even if the internal
scoring function keeps improving. The green curve depicts the AUC of the RLS model trained using
features selected by single-locus p-value based filter method, Fisher’s exact test, which is run with the same
external training/test split as the greedy selection method. Similarly to the blue curve, the green one also
stops improving soon after a relatively small set of features has been selected. The data used in the
experiments is the Wellcome Trust Case Controls Consortium (WTCCC) Hypertension dataset combined
with the UK National Blood Services’ controls.
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lap between the examined cohorts [48]. However, here one should consider whether
the aim is to validate the predictive model itself (e.g. using external cross-validation or
independent validation samples), or the predictive variants selected by the model (repli-
cation of the model construction or its application to separate cohorts) [49].
Through the development of better model validation techniques and unbiased exam-
ination of all feature subsets in genome-wide scale, we are likely to continuously im-
prove the accuracy of the predictive models and increase their reproducibility on
independent population samples. A challenge here is that differences in the population
genetic structure, attributable to confounding factors such as the ethnicity or ancestry
of the subjects, may result in highly heterogeneous datasets with a number of hidden
subject sub-groups, which may associate with divergent disease phenotypes and
therefore cause an increased false-positive rates [50]. Related to this, while there are
comparisons among various feature selection methods and predictive modeling
frameworks on individual cohorts [23,24,27], there is not yet any definitive results
whether one method will universally lead to optimal results in other subject cohorts or
populations. Such confounding variability should also be taken into account in the
model construction and evaluation, perhaps in some form of population stratified
cross-validation. Failure to replicate a genetic association should not only be considered
as a negative result, as it may also provide important clues about genetic architecture
among study populations or genetic interactions among risk variants [51]. When
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locus filters, will not alone be able to provide most optimal results, while in extremely
large datasets, wrapper methods may pose computational limitations if combined with
complex prediction models. Finally, even though the improvements obtained by the
machine learning wrappers, compared to those from the traditional p-value based
filters, may seem quite modest (e.g. Figure 1), it may turn out that even slight
improvements in the predictive accuracy can result in significant clinical benefits.
Moreover, it is argued that the modest predictive improvements may be further
aggregated through pathway and network-level analyses of the selected variants.Molecular networks as a prior information for constructing predictive models
Even in the absence of significant single-locus marginal effects, multiple genetic loci
from a number of molecular pathways may act synergistically and lead to disease
phenotype when combined. Therefore, it has become popular to map the genetic loci
identified in GWA or NGS studies to established biological pathways in order to eluci-
date the potential cellular mechanisms behind the observed genetic and phenotypic
variation. There exist a wide variety of tools and guidelines on how to implement such
pathway analyses in the context of genetic association studies [52-56]. Building on
approaches originally developed in the context of microarray gene expression
experiments, the common theme in the pathway analysis approaches is that they exam-
ine whether a group of related loci in the same biological pathway are jointly associated
with a trait of interest. In line with the observations in microarray gene expression
studies, it has been shown that in those cases where there is only a modest overlap in
the variant or gene-level findings between different studies, due to factors such as
differences in the genetic structure, the pathway-level associations may be much more
reproducible even between different study populations [57-60]. These findings support
the concept that individuals with the same disease phenotype may have marked inter-
individual genetic heterogeneity in the sense that their disease predisposing variants
may lie in distinct loci within the same or related pathways [14]. Machine learning-
based predictive models constructed upon gene expression profiling have already
shown the benefits of using pathway activities as features in terms of improved classifi-
cation accuracy, compared to those models that consider merely individual gene ex-
pression levels [61]. It has also been demonstrated in the context of GWA datasets that
pathway analysis can provide not only mechanistic insights but also improved discrim-
ination power using tailored statistical data mining techniques, such as HyperLasso
[62] or so-called pathways of distinction analysis (PoDA) [63].
A limitation of constructing predictive models for a disease merely on the basis of
established pathways is that these models may become biased toward already known
biological processes, thereby potentially missing novel yet causal mechanisms predictive
of the disease risk [64]. It may also not be so straightforward to infer the set of
pathways that should be included in the model building process, in the absence of any
a priori knowledge. Perhaps more importantly, statistical analysis of separate biological
pathways or distinct gene sets undermines the effect of pathway cross-talk behind dis-
ease development, in which multiple genetic variants from distinct molecular pathways
show synergistic contribution to the disease phenotype. In practice, the regulatory
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interconnected networks of physical and functional interplay between a multitude of
pathway components [16]. As an example, we constructed a network representation for
variants predictive of type 1 diabetes risk, which illustrate a selected portion of the
number of pathways and their relationships that may be predictive of the disease onset
(Figure 2). Given such high degree of interconnectivity, not only between the genetic
variants but also among the implicated pathways, it is not surprising that the first ma-
chine learning frameworks for explicitly accounting epistatic gene-gene interactions
have focused mostly on measures from information theory, such as those based on
additive models, information gain, conditional entropy, or mutual information
[24,65-67]. These models treat pairwise genetic interactions in a way that closely
resembles the classic definition of epistasis, involving single and double-deletion
experiments in model organisms [68]. However, even if allowing computationally effi-
cient exploration of genetic interactions, a posteriori detection and heuristic search
schemes cannot guarantee that the detected pairs of genetic risk factors will eventually
be the most essential ones for the improved predictive power among all the possible
variant combinations.
Toward more systematic network-centric analysis of genetic variants on a genome-
wide scale, molecular interaction networks can be used as a priori information in the
predictive models, in the form e.g. filters or integrators, with the aim of either reducingFigure 2 Sample network visualization constructed for type 1 diabetes. The risk variants were selected
using the greedy RLS on the WTCCC type 1 diabetes GWAS data and the UK National Blood Services’
controls, extended with those genes selected in another work [62]. The biological processes and pathways
were then mapped using DAVID [112,113], and the network visualization was done with the Enrichment
Map plugin for Cytoscape [114,115]. The nodes represent pathways and the edges are the amount of
overlap between the members of the pathways. The visualized network represents a selected sub-network
of complex interconnections and cross-talks between a number of pathways, including MHC-related
processes and other biological pathways associated with diabetes phenotypes. The pathways were
identified initially using DAVID, with the criteria that they demonstrate enrichment when compared to the
genome-wide background. The retrieved pathways were subsequently filtered in Cytoscape through the
Enrichment Map plugin using the false-discovery rate and overlap coefficient to filter out
non-significant pathways.
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signal-to-noise ratio through external knowledge incorporated in terms of physical or
functional molecular networks [69,70]. Network graphs provide a convenient mathem-
atical framework for modeling, integrating and mining high-dimensional genomic
datasets, in which to present the relationships among genetic loci, genes and diseases
[64,69-72]. Successful examples of combining individual-level gene expression
measurements with background networks of physical interactions between proteins
and transcription factor targets have demonstrated that it is possible to identify and
make use of disease-specific sub-networks, so-called modules, in order to reduce both
the number of false positives and negatives, caused by factors such as technical vari-
ability and genetic heterogeneity, respectively, as well as to improve individual-level
prediction of clinical outcomes, such as cancer metastasis or survival time [64,73-75].
There are also studies in the context of GWA datasets, which motivate the use of net-
work connectivity structures, such as sub-network modules or highly-connected net-
work hubs [22,64,76-78], as aggregate features in the disease prediction models.
However, what has been largely missing is a systematic approach that could combine
network topology as a priori information when constructing predictive models. Re-
cently, a particularly interesting approach was introduced as a principled method that
uses genetic algorithms guided by the structure of a given gene interaction network to
discover small groups of connected variants, which are jointly associated with a disease
outcome on a genome-wide scale [79]. Combined with more efficient, wrapper-type of
search algorithms, such network-guides feature selection approaches could be scaled-
up in the future to enable extracting also larger sub-networks with improved predict-
ive capability.Future directions: lessons from model organisms and individualized medicine
Given the rather modest progress made so far in pursuing the expensive and subopti-
mal route of current drug discovery, there has been much interest lately in moving to-
wards personalized medicine strategies [80,81]. Another major paradigm shift in
disease treatment is moving away from the traditional 'one target, one drug' strategy to-
wards the so-called network pharmacology, a novel paradigm which provides more
global understanding of the mechanisms behind disease processed and drug action by
considering drug targets in their context of biological networks and pathways [82].
These emerging paradigms can offer holistic information on disease networks and drug
responses, with the aim of identifying more effective drug targets and their
combinations tailored for individualized treatment strategies. A prime challenge in
developing such strategies is to understand how genes function as interaction networks
to carry out and regulate cellular processes, and how perturbations in these cellular
networks cause certain phenotypes, such as human diseases, in some individuals, but
not in the others. There has been active research in model organisms addressing the
question why disease causing mutations do not cause the disease in all individuals [14].
Recent studies in yeast Saccharomyces cerevisiae, worm Caenorhabditis elegans, and fly
Drosophila melanogaster have demonstrated the importance of incorporating functional
genetic interaction partners of the mutated genes in the prediction of phenotypic vari-
ation and mutational outcomes at an individual level [83-85]. Pilot studies in human
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GWA or NGS studies, may indeed yield useful and clinically relevant information for
individual patients [1,2]. However, a number of experimental, modeling and computa-
tional challenges have to be solved before the promises of personalized medicine can
be translated into routine clinical practice [5,81,86].
From the experimental point of view, the whole-genome sequencing efforts will en-
able us to delve deeper into the individual genomes by elucidating the role of low-
frequency variants in the genetic architecture of complex diseases. The sequencing
efforts, such as the 1000 Genomes project [10], are also being used to subsequently ex-
tend the coverage of the existing GWA datasets by means of imputation methods and
population-specific reference haplotypes [87,88]. However, while the emerging shift
from population-level common variants toward individual-level rare or even personal
variants holds great promise for medical research, it also represents with unique model-
ing challenges; in particular, the traditional statistical modeling frameworks that were
developed under settings where the number of study samples greatly exceeds the num-
ber of study variables may not to be ideally suited for the personalized medicine
settings, in which the individuals and disease subtypes are stratified into increasingly
smaller subgroups [89]. Although machine learning methods are better targeted at
individual-level prediction making, the feature selection methods would also benefit
from more stratified options, for instance, in terms of enabling phenotype-specific gen-
etic features, rather than assuming that all subjects share the same panel of predictive
genotypes. Also, since the binary disease outcomes, typically in the form of case or con-
trol dichotomy, may not provide the most reliable study phenotypes, the predictive
modeling frameworks might become more successful for predicting quantitative pheno-
typic traits [90-92]. This also raises related modeling questions, such as how to encode
imputed variants (e.g. expected or most likely genotype), how to treat missing data (ex-
clude or impute), or how to model the variants and their interactions (multiplicative,
additive, recessive or dominant models) [90-94]; these all may have an important effect
on the prediction performance, especially in the presence of epistatic interactions at an
individual level.
From the computational perspective, the ever increasing sizes of the raw NGS and
imputed GWA datasets pose great challenges to the computational algorithms. For in-
stance, while systematic genetic mappings in model organisms have revealed wide-
spread genetic interactions within individual species [85,95-97], epistasis interactions
have remained extremely difficult to identify on a global scale in human populations.
This can be attributed to the vast number of potential interaction partners, along with
complex genotype-phenotype relationships and their individual-level differences.
Improvements in computational performance have recently been obtained through ef-
fective usage of computer hardware, for instance, through graphics processing units,
Cloud-based computing environments, or multithread parallelization, when exploring
genetic variants or their interactions in GWA studies [98-101]. Furthermore, since the
memory consumption in the high-dimensional NGS applications can form even a
tighter bottleneck than the running time, there is also a need to develop space-efficient
implementations, which trade running time for decreased memory consumption [23].
Lessons from model organisms, such as yeast, have also demonstrated that data inte-
gration between complementary screening approaches, either functional or physical
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gone undetected by any of the individual approaches alone [95,96,102]. Also, integrating
diverse phenotypic readouts facilitates genetic interaction screens [103], and Bayesian
models have been shown especially useful for making use of multiple traits, gene-gene or
gene-environment interactions in disease risk prediction [104]. Finally, visualization
algorithms that can capture the hierarchical modularity of the physical and functional
interaction networks may help reveal interesting biological patterns and relationships
within the data, such as pathway components and biological processes, which can be fur-
ther investigated by follow-up computational and/or experimental analyses [105].
Better understanding of the general design principles underlying genetic interaction
networks in model organisms can provide important insights into the relationships be-
tween genotype and phenotype, toward better understanding and treating also complex
human diseases, such as cancers. Cancer phenotypes are known to arise and develop
from various genetic alterations, and therefore the same therapy often results in differ-
ent treatment responses. Moreover, the underlying genetic heterogeneity results in
alterations within multiple molecular pathways, which lead to various cancer phenotypes
and make most tumors resistant to single agents. Cancer sequencing efforts, such as The
Cancer Genome Atlas (TCGA), are systematically characterizing the structural basis of
cancer, by identifying the genomic mutations associated with each cancer type. These
efforts have revealed tremendous inter-individual mutational and phenotypic heterogen-
eity, which renders it difficult to translate the genetic information into clinically actionable
individualized treatment strategies [106-108]. Therefore, integrating the structural gen-
omic information with systematic functional assessment of genes for their contribution to
genetic dependencies and cancer vulnerabilities, such as oncogenic addictions or synthetic
lethalities [109,110], is likely needed for providing more comprehensive insight into the
molecular mechanisms and pathways behind specific cancer types and for improving their
prevention, diagnosis and treatment [106,111]. Machine learning-based predictive model-
ing approaches are well-powered to make the most of the exciting functional and genetic
screens toward revealing hidden genetic variants and their interactions behind cancer and
other complex phenotypes. When combined with network analyses, these integrated
systems medicine approaches may offer the possibility to identify key players and their
relationships responsible for multi-factorial behavior in disease networks, with many diag-
nostic, prognostic and pharmaceutical applications.Competing interests
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